# Medical Cannabis Evidence-Based Care: CBD for Fibromyalgia

> **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637)
> **Publisher:** CED Clinic (https://cedclinic.com)
> **Canonical URL:** https://cedclinic.com/cannabinoid-clinical-trials-cbd-for-fibromyalgia-evidence-2/
> **Published:** 2026-03-12T13:01:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T17:09:32-04:00
> **Clinical Summary:** Explore cannabinoid clinical trials CBD for fibromyalgia evidence and understand current research on CBD's effectiveness in fibromyalgia pain management.

---

#### Clinical Takeaway

In this randomized, double-blind, placebo-controlled trial, CBD did not demonstrate superiority over placebo in reducing pain among patients with fibromyalgia. The findings do not support CBD as an effective treatment for fibromyalgia pain based on current evidence. Clinicians should communicate realistic expectations to patients who are considering CBD for this condition.

### #7 Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.

**Citation:** Rasmussen Marianne Uggen et al. *Cannabidiol versus placebo in patients with fibromyalgia: a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.* Annals of the rheumatic diseases. 2026. PMID: 40846590.

**Study type:** Journal Article, Randomized Controlled Trial  | 
 **Topic area:** Cannabidiol  | 
 **CED Score:** 11

Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2

 Why This Matters
 This randomized, double-blind, placebo-controlled trial provides the rigorous evidence needed to evaluate CBD’s analgesic efficacy in fibromyalgia, a condition for which current pharmacotherapy has limited effectiveness and significant adverse effects. The findings establish a necessary evidentiary foundation for clinical decision-making regarding CBD use in fibromyalgia management and help determine whether this agent warrants consideration as an alternative or adjunctive treatment option. Given widespread off-label CBD use in fibromyalgia patients despite limited efficacy data, this study addresses a critical gap between [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/) and [evidence-based medicine](https://cedclinic.com/digital-health-expertise-modern-challenge/).

**Quality Gate Alerts:**

- Preclinical only

**Abstract:** OBJECTIVES: Cannabidiol (CBD) is used to alleviate fibromyalgia pain despite limited evidence for efficacy. This study assessed the efficacy and safety of CBD vs placebo in patients with fibromyalgia, hypothesising that CBD would be superior to placebo in reducing pain. METHODS: In this single-centre, double-blind, randomised, placebo-controlled trial, patients diagnosed with fibromyalgia were recruited from a specialised outpatient clinic in Denmark. Eligible participants were randomised 1:1 and stratified by sex, defined as biological sex assigned at birth based on physical anatomy. Age (<45 vs ≥45), and pain level (<7 vs ≥7) on a 0 to 10 numeric rating scale (NRS) to receive 50 mg plant-derived CBD or placebo tablets. The primary outcome was change in pain intensity at week 24, assessed on the NRS pain subitem in the revised Fibromyalgia Impact Questionnaire in the intention-to-treat population. Adverse events were monitored throughout the study in the safety population. RESULTS: Of 273 participants screened for eligibility, 200 were included and randomised to receive CBD (n = 100) or placebo (n = 100). At week 24, mean change in pain intensity was -0.4 points (95% CI: -0.82 to 0.08) in the CBD group and -1.1 points (95% CI: -1.53 to -0.63) in the placebo group, corresponding to a between-group difference of -0.7 points (95% CI: -1.2 to -0.25; P = .0028) favouring placebo. Adverse events were generally mild and evenly distributed between groups. CONCLUSIONS: The findings do not support CBD 50 mg daily as an analgesic supplement for patients with fibromyalgia. CLINICALTRIALS: gov number: NCT04729179.

 Clinical Perspective

This Danish randomized controlled trial adds meaningful data to the fibromyalgia-CBD evidence base, though several factors warrant cautious interpretation before implementation. Single-center studies have inherent limitations in generalizability, and fibromyalgia’s heterogeneous presentation means results may not apply uniformly across all patient phenotypes; additionally, the trial’s methodology appears incomplete in the available abstract, making it difficult to assess for potential biases in outcome measurement or follow-up duration. The growing clinical use of CBD for fibromyalgia pain often outpaces rigorous evidence, so this study’s contribution to either supporting or refuting efficacy claims will meaningfully influence counseling conversations with patients already using or considering CBD. For practitioners, the key implication is that while this trial may help refine our understanding of CBD’s role in fibromyalgia management, individual patient response remains variable and decisions should incorporate baseline symptom severity, comorbidities, concurrent medications, and realistic outcome expectations rather than relying on any single study.

 | 

Further Reading
Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 12, 2026](https://cedclinic.com/cannabis-regulatory-updates-march-2026/)
CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/)
Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/)

[View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40846590/)[DOI ↗](https://doi.org/10.1016/j.ard.2025.07.008)

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

Physician-Led, Whole-Person Care
A doctor who takes the time to truly understand you.
Personal care that starts with listening and is guided by experience and ingenuity.

Health, Longevity, Wellness
One-on-One Cannabis Guidance
Metabolic Balance

 [Leave a Message](https://cedclinic.com/contact/)
 [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/)
 [Medical Consulting](https://cedclinic.com/book/)
 [Cannabis Care](https://cedclinic.com/book/)
 

 [https://cedclinic.com/contact/](https://cedclinic.com/contact/)
 

RELATED READING AT CED CLINIC

Continue exploring the evidence

[cannabinoid clinical trials: CBD vs Placebo Fibromyalgia](https://cedclinic.com/cbd-fibromyalgia-placebo-controlled-trial-results/)

Detailed analysis of [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) comparing CBD and placebo in fibromyalgia patients, providing insights into efficacy and safety.

[Read More](https://cedclinic.com/cbd-fibromyalgia-placebo-controlled-trial-results/)

[`CBD for Fibromyalgia: Clinical Trial Evidence Reviewed`](https://cedclinic.com/cbd-fibromyalgia-clinical-trial-evidence/)

Comprehensive review of clinical trial evidence on CBD use for fibromyalgia, highlighting key findings and clinical implications.

[Explore Now](https://cedclinic.com/cbd-fibromyalgia-clinical-trial-evidence/)

[Cannabidiol for Fibromyalgia: Evidence-Based Cannabis Care](https://cedclinic.com/cbd-fibromyalgia-clinical-trial-evidence/)

An evidence-based discussion on cannabidiol’s role in fibromyalgia care, focusing on clinical trial data and [patient outcomes](https://cedclinic.com/uk-medical-cannabis-chronic-pain-outcomes-patient-insights/).

[Learn More](https://cedclinic.com/cbd-fibromyalgia-clinical-trial-evidence/)

Have thoughts on this? Share it:

[X Share on X](https://twitter.com/intent/tweet?text=Medical%20Cannabis%20Evidence-Based%20Care%3A%20CBD%20for%20Fibromyalgia&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-cbd-for-fibromyalgia-evidence%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-cbd-for-fibromyalgia-evidence%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Medical%20Cannabis%20Evidence-Based%20Care%3A%20CBD%20for%20Fibromyalgia%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-cbd-for-fibromyalgia-evidence%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/)

 

### Related

---

### Verification & Medical Governance

- **Lead Clinical Author:** Benjamin Caplan, MD
- **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House).
- **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`).
- **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/).
- **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637).
- **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).
